The Gene Expression Response of Breast Cancer to Growth Regulators: Patterns and Correlation with Tumor Expression Profiles

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7158-7166

  Cunliffe, Heather E ^a   Ringnér, Markus ^b   Bilke, Sven ^c   Walker, Robert L ^a   Cheung, Jennifer M ^a   Chen, Yidong ^a   Meltzer, Paul S ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b LUND UNIVERSITY   (Sweden)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTIESTROGEN; ANTIGESTAGEN; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GESTAGEN; GROWTH FACTOR; HORMONE; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE 1 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROMEGESTONE; RETINOIC ACID; STEROID; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GROWTH REGULATION; HISTOGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ALGORITHMS; BREAST NEOPLASMS; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH SUBSTANCES; HUMANS; MAP KINASE SIGNALING SYSTEM; MULTIGENE FAMILY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ESTROGEN;

EID: 0242442571     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Salh, B., Marotta. A., Matthewson, C., Ahluwalia, M., Flint, J., Owen, D., and Pelech, S. Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res., 19: 731-740, 1999.
2. Mueller, H., Flury, N., Eppenberger-Castori, S., Kueng, W., David, F., and Eppenberger, U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients, Int. J. Cancer, 89: 384-388, 2000.
3. Darbon, J. M., Valette, A., and Bayard, F. Phorbol esters inhibit the proliferation of MCF-7 cells. Possible implication of protein kinase C. Biochem. Pharmacol., 35: 2683-2686, 1986.
4. de Vente, J. E., Kukoly, C. A., Bryant, W. O., Posekany, K. J., Chen, J., Fletcher, D. J., Parker, P. J., Pettit, G. J., Lozano, G., Cook, P. P., et al. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J. Clin. Investig., 96: 1874-1886, 1995.
5. Lee, C. S., Koga, M., and Sutherland, R. L. Modulation of estrogen receptor and epidermal growth factor receptor mRNAs by phorbol ester in MCF 7 breast cancer cells. Biochem. Biophys. Res. Commun., 162: 415-421, 1989.
6. Saceda, M., Knabbe, C., Dickson, R. B., Lippman, M. E., Bronzert, D., Lindsey, R. K., Gottardis, M. M., and Martin, M. B. Post-transcriptional destabilization of estrogen receptor mRNA in MCF-7 cells by 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem., 266: 17809-17814, 1991.
7. Tzukerman, M., Zhang, X. K., and Pfahl, M. Inhibition of estrogen receptor activity by the tumor promoter 12-O-tetradeconylphorbol-13-acetate: a molecular analysis. Mol. Endocrinol., 5: 1983-1992, 1991.
8. Gudas, L. J. Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth Differ., 3: 655-662, 1992.
9. Hong, W. K., and Sporn, M. B. Recent advances in chemoprevention of cancer. Science (Wash. DC), 278: 1073-1077, 1997.
10. Budd, G. T., Adamson, P. C., Gupta, M., Homayoun, P., Sandstrom, S. K., Murphy, R. F., McLain, D., Tuason, L., Peereboom, D., Bukowski, R. M., and Ganapathi, R. Phase I/II trial of all-trans-retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res., 4: 635-642, 1998.
11. Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C., Lashkari, D., Shalon, D., Brown, P. O., and Botstein, D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA, 96: 9212-9217, 1999.
12. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O., and Botstein, D. Molecular portraits of human breast tumours. Nature (Lond.), 406: 747-752, 2000.
13. Gruvberger, S., Ringner, M., Chen, Y., Panavally, S., Saal, L. H., Borg, A., Ferno, M., Peterson, C., and Meltzer, P. S. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res., 61: 5979-5984, 2001.
14. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, D., Eystein Lonning, P., and Borresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 98: 10869-10874, 2001.
15. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond.), 415: 530-536, 2002.
16. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E. T., Friend, S. H., and Bernards, R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 347: 1999-2009, 2002.
17. West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R., Zuzan, H., Olson, J. A., Jr., Marks, J. R., and Nevins, J. R. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. USA, 98: 11462-11467, 2001.
18. Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., Pergamenschikov, A., Lee, J. C., Lashkari, D., Shalon, D., Myers, T. G., Weinstein, J. N., Botstein, D., and Brown, P. O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet., 24: 227-235, 2000.
19. Charpentier, A. H., Bednarek, A. K., Daniel, R. L., Hawkins, K. A., Laflin, K. J., Gaddis, S., MacLeod, M. C., and Aldaz, C. M. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res., 60: 5977-5983, 2000.
20. Soulez, M., and Parker, M. G. Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. J. Mol. Endocrinol., 27: 259-274, 2001.
21. Lobenhofer, E. K., Bennett, L., Cable, P. L., Li, L., Bushel, P. R., and Afshari, C. A. Regulation of DNA replication fork genes by 17β-estradiol. Mol. Endocrinol., 16: 1215-1229, 2002.
22. Wan, Y., and Nordeen, S. K. Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells. Mol. Endocrinol., 16: 1204-1214, 2002.
23. Seth, P., Krop, I., Porter, D., and Polyak, K. Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene, 21: 836-843, 2002.
24. Inoue, A., Yoshida, N., Omoto, Y., Oguchi, S., Yamori, T., Kiyama, R., and Hayashi, S. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J. Mol. Endocrinol., 29: 175-192, 2002.
25. Levenson, A. S., Kliakhandler, I. L., Svoboda, K. M., Pease, K. M., Kaiser, S. A., Ward, J. E., III, and Jordan, V. C. Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha. Br. J. Cancer, 87: 449-456, 2002.
26. Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., and Auricchio, F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J., 15: 1292-1300, 1996.
27. Improta-Brears, T., Whorton, A. R., Codazzi, F., York, J. D., Meyer, T., and McDonnell, D. P. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad. Sci. USA, 96: 4686-4691, 1999.
28. Font de Mora, J., and Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol., 20: 5041-5047, 2000.
29. Filardo, E. J., Quinn, J. A., Bland, K. I., and Frackelton, A. R., Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol., 14: 1649-1660, 2000.
30. Azorsa, D. O., Cunliffe, H. E., and Meltzer, P. S. Association of steroid receptor coactivator AIB1 with estrogen receptor-α in breast cancer cells. Breast Cancer Res. Treat, 70: 89-101, 2001.
31. Khan, J., Simon, R., Bittner, M., Chen, Y., Leighton, S. B., Pohida, T., Smith, P. D., Jiang, Y., Gooden, G. C., Trent, J. M., and Meltzer, P. S. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res., 58: 5009-5013, 1998.
32. DeRisi, J., Penland, L., Brown, P. O., Bittner, M. L., Meltzer, P. S., Ray, M., Chen, Y., Su, Y. A., and Trent, J. M. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet., 14: 457-460, 1996.
33. Khan, J., Bittner, M. L., Chen, Y., Meltzer, P. S., and Trent, J. M. DNA microarray technology: the anticipated impact on the study of human disease. Biochim. Biophys. Acta, 1423: M17-M28, 1999.
34. Chen, Y., Dougherty, E. R., and Bittner, M. L. Ratio-based decisions and the quantitative analysis of cDNA microarray images. J. Biomed. Optics, 2: 364-374, 1997.
35. Chen, Y., Kamat, V., Dougherty, E. R., Bittner, M. L., Meltzer, P. S., and Trent, J. M. Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics, 18: 1207-1215, 2002.
36. Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., Harris, M. A., Hill, D. P., Issel-Tarver, L., Kasarskis, A., Lewis, S., Matese, J. C., Richardson, J. E., Ringwald, M., Rubin, G. M., and Sherlock, G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet., 25: 25-29, 2000.
37. Diel, P., Smolnikar, K., and Michna, H. The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down-regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res. Treat, 58: 87-97, 1999.
38. Bundred, N. J., Anderson, E., Nicholson, R. I., Dowsett, M., Dixon, M., and Robertson, J. F. Fulvestrant, an estrogen receptor down-regulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res., 22: 2317-2319, 2002.
39. Vladusic, E. A., Hornby, A. E., Guerra-Vladusic, F. K., Lakins, J., and Lupu, R. Expression and regulation of estrogen receptor β in human breast tumors and cell lines. Oncol Rep., 7: 157-167, 2000.
40. Jeng, M. H., Parker, C. J., and Jordan, V. C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res., 52: 6539-6546, 1992.
41. Schoonen, W. G., Joosten, J. W., and Kloosterboer, H. J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: 1. MCF-7 cell lines. J Steroid Biochem Mol Biol, 55: 423-437, 1995.
42. Fabbro, D., Regazzi, R., Costa, S. D., Borner, C., and Eppenberger, U. Protein kinase C desensitization by phorbol esters and its impact on growth of human breast cancer cells. Biochem. Biophys. Res. Commun., 135: 65-73, 1986.
43. Nutt, J. E., Harris, A. L., and Lunec, J. Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-β1 genes in breast tumour cells. Br. J. Cancer, 64: 671-676, 1991.
44. Shanmugam, M., Krett, N. L., Maizels, E. T., Murad, F. M., Rosen, S. T., and Hunzicker-Dunn, M. A role for protein kinase C δ in the differential sensitivity of MCF-7 and MDA-MB 231 human breast cancer cells to phorbol ester-induced growth arrest and p21(WAF1/CIP1) induction. Cancer Lett., 172: 43-53, 2001.
45. Ueda, Y., Hirai, S., Osada, S., Suzuki, A., Mizuno, K., and Ohno, S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem., 271: 23512-23519, 1996.
46. Hausser, A., Storz, P., Hubner, S., Braendlin, I., Martinez-Moya, M., Link, G., and Johannes, F. J. Protein kinase Cμ selectively activates the mitogen-activated protein kinase (MAPK) p42 pathway. FEBS Lett, 492: 39-44, 2001.
47. Keshamouni, V. G., Mattingly, R. R., and Reddy, K. B. Mechanism of 17-β-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-δ. J. Biol. Chem., 277: 22558-22565, 2002.
48. Stoica, A., Saceda, M., Doraiswamy, V. L., Coleman, C., and Martin, M. B. Regulation of estrogen receptor α gene expression by epidermal growth factor. J. Endocrinol., 165: 371-378, 2000.
49. Wu, R. C., Qin, J., Hashimoto, Y., Wong, J., Xu, J., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I κ B kinase. Mol. Cell. Biol., 22: 3549-3561, 2002.
50. Levin, E. R. Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol. Metab., 10: 374-377, 1999.
51. Wehling, M. Specific, nongenomic actions of steroid hormones. Annu. Rev. Physiol., 59: 365-393, 1997.
52. Collins, P., and Webb, C. Estrogen hits the surface. Nat. Med., 5: 1130-1131, 1999.
53. Flototto, T., Djahansouzi, S., Glaser, M., Hanstein, B., Niederacher, D., Brumm, C., and Beckmann, M. W. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. Horm. Metab. Res., 33: 451-457, 2001.
54. Filardo, E. J., Quinn, J. A., Frackelton, A. R., Jr., and Bland, K. I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol., 16: 70-84, 2002.
55. Sigurdsson, H., Baldetorp, B., Borg, A., Dalberg, M., Ferno, M., Killander, D., and Olsson, H. Indicators of prognosis in node-negative breast cancer. N. Engl. J. Med., 322: 1045-1053, 1990.
56. Zajchowski, D. A., Bartholdi, M. F., Gong, Y., Webster, L., Liu, H. L., Munishkin, A., Beauheim, C., Harvey, S., Ethier, S. P., and Johnson, P. H. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res., 61: 5168-5178, 2001.
57. Malmstrom, P., Bendahl, P. O., Boiesen, P., Brunner, N., Idvall, I., and Ferno, M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J. Clin. Oncol., 19: 2010-2019, 2001.